Life beyond bortezomib: increasing treatment options in refractory myeloma

Leuk Lymphoma. 2016;57(6):1251-3. doi: 10.3109/10428194.2016.1153090. Epub 2016 Mar 1.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / therapeutic use
  • Bortezomib*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Pyrazines / therapeutic use

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib